Physician profile
Nimisha Deb
NPI 1932152089
$2,367.55
in general payments reported to CMS, 2019-2025
11 companies · $91.58 in 2025
The $91.58 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2022: $85.66 · 2023: $1,286 · 2025: $91.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,000 · Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,000.00 |
| Food and Beverage | $377.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gt Medical Technologies, INC | $1,191.90 | 2023 | Gammatile |
| Brainlab, INC. | $618.25 | 2019 | |
| Theragenics Corporation | $183.44 | 2019 | |
| Siemens Medical Solutions USA, INC. | $85.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $69.41 | 2025 | |
| Varian Medical Systems, INC. | $68.75 | 2019 | |
| Novocure INC. | $44.44 | 2023 | Optune |
| Astrazeneca Pharmaceuticals Lp | $33.99 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.84 | 2023 | Zepzelca |
| Boston Scientific Corporation | $24.70 | 2023 | Spaceoar Vue System - 10ml |
| Teleflex LLC | $22.17 | 2025 | Barrigel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimisha Deb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.